Lifeworks Advisors LLC Has $4.15 Million Position in Abbott Laboratories $ABT

Lifeworks Advisors LLC raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 41.3% in the first quarter, Holdings Channel reports. The fund owned 40,458 shares of the healthcare product maker’s stock after acquiring an additional 11,817 shares during the period. Lifeworks Advisors LLC’s holdings in Abbott Laboratories were worth $4,154,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Freemont Management S.A. raised its stake in shares of Abbott Laboratories by 197.2% in the fourth quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after acquiring an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories during the 4th quarter worth approximately $116,580,000. Danica Pension Livsforsikringsaktieselskab acquired a new stake in Abbott Laboratories during the 3rd quarter valued at $185,640,000. Thrivent Financial for Lutherans increased its holdings in Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares in the last quarter. Finally, Net Worth Advisory Group bought a new position in Abbott Laboratories in the 4th quarter valued at $1,366,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 0.0%

NYSE ABT opened at $93.97 on Monday. The stock has a market capitalization of $163.69 billion, a P/E ratio of 26.32, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The stock has a fifty day moving average of $89.21 and a 200-day moving average of $103.09.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 70.59%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ABT has been the topic of several research analyst reports. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, July 7th. Benchmark cut their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Barclays reduced their price target on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research report on Monday, April 20th. Jefferies Financial Group lowered their price objective on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Finally, UBS Group dropped their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $118.42.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.